Clinical Trial Detail

NCT ID NCT02443337
Title A Study of LY3023414 and Necitumumab in Squamous Lung Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

lung squamous cell carcinoma

Therapies

Necitumumab

LY3023414

Age Groups: adult

No variant requirements are available.